VCYT250117P22500
- 0.00
- 0.000.00%
Veracyte Newsroom
Breakeven Is Near for Veracyte, Inc. (NASDAQ:VCYT)
Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?
The Zacks Analyst Blog Highlights McKesson, Doximity and Veracyte
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave
Express News | Veracyte Inc : Guggenheim Raises Target Price to $45 From $40
Those Who Invested in Veracyte (NASDAQ:VCYT) a Year Ago Are up 68%
If You Invested $1000 in Veracyte a Decade Ago, This Is How Much It'd Be Worth Now
Express News | Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in Nccn® Prostate Cancer Guidelines
Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN Prostate Cancer Guidelines
Goldman Sachs Downgrades Veracyte(VCYT.US) to Hold Rating
Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37
The hidden winner in the USA election? Cathie Wood's ARKK hit a new high for the year, all thanks to these heavily weighted stocks!
The strong rise of ARKK is mainly attributed to the increase in its heavy holdings, Tesla, and cryptos-related companies, Coinbase and Robinhood.
Veracyte, Inc. (NASDAQ:VCYT) Held Back By Insufficient Growth Even After Shares Climb 30%
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Veracyte Is Maintained at Underweight by Morgan Stanley
Express News | Veracyte Inc : Morgan Stanley Raises Target Price to $28 From $26
Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside
Wolfe Research Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $50
Veracyte Insider Sold Shares Worth $585,663, According to a Recent SEC Filing
ARKK's Holdings Ranked by SA Quant Grades